Status: Not yet recruiting
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal. The primary endpoint is progression-free survival (PFS).
Participants needed: 67
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Hao ZengUpdated: Jul 26, 2024Locations: 1
Eligibility criteria
Age ≥18 years and ≤75 years, any gender. [+7]
Pathologically diagnosed with non-renal cell carcinoma, collecting duct carcinom... [+22]